Jiangsu Hengrui Pharmaceuticals Co.,Ltd (HKG:1276)

Market Cap	417.86B +35.7%
Revenue (ttm)	33.86B +19.2%
Net Income	8.16B +37.1%
EPS	1.27 +34.9%
Shares Out	n/a
PE Ratio	51.20
Forward PE	36.98
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,683,796
Average Volume	2,586,296
Open	63.85
Previous Close	62.35
Day's Range	63.85 - 66.20
52-Week Range	52.50 - 95.20
Beta	n/a
RSI	43.74
Earnings Date	Mar 26, 2026

About HKG:1276

Jiangsu Hengrui Pharmaceuticals Co.,Ltd, a pharmaceutical company, researches, develops, manufactures, and commercializes medicines to address unmet clinical needs in China and internationally. It develops medicines in the areas of oncology, metabolic and cardiovascular, immunological and respiratory, neuroscience, pain management, infectious, respiratory system, hematological, ophthalmology, and autoimmune and other diseases. The company was founded in 1970 and is headquartered in Lianyungang, China.

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1970
• Employees: 20,238
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 1276

Financial Performance

In 2024, HKG:1276's revenue was 27.98 billion, an increase of 22.63% compared to the previous year's 22.82 billion. Earnings were 6.34 billion, an increase of 47.28%.

Financial numbers in CNY